Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1245-1251

  Vicente, Colin ^a   Walker, John ^a,b   Buys, Yvonne ^c   Einarson, Thomas R ^a,d   Covert, David ^e   Iskedjian, Michael ^a,f  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b BROCK UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ALCON RESEARCH LTD   (United States)

^f NONE   (Canada)

Author keywords

Costs; Disease stability; Glaucoma; Intraocular pressure; Visual field

Indexed keywords

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PHYSICIAN; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL FIELD;

EID: 4344627620     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004358     Document Type: Article

References (14)

1. Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93
2. Hyman L, Wu S, Connell A, Schachat A, Hennis A, Leske M. Prevalence and causes of visual impairment in the Barbados Eye Study. Ophthalmology 2001;108:1751-6
3. Quigley H, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91
4. Klein R, Klein B, Scot E, Moss M. Age-related eye disease and survival: the Beaver Dam Eye Study. Arch Ophthalmol 1995;113:333-9
5. Coleman A. Glaucoma. Lancet 1999;354:1803-10
6. Kerrigan-Baumrind L, Quigley H, Pease M, Kerrigan D, Mitchell R. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 2000;41:741-8
7. Jones S, Vernon S, Cater L, Henry D. Costing a community based screening programme for the detection of glaucoma. Eye 1990;4:98-102
8. Ontario Ministry of Health. Schedule of Benefits; Physician Services under the Health Insurance Act. Toronto: Institutional Services Branch, Ministry of Health; 1993
9. Ministry of Health. Ontario Drug Benefit Formulary Comparative Drug Index. Toronto: Queen's Printer for Ontario; 2001
10. Fiscella R, Geller J, Gryz L, Wilensky J, Viana M. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999;128:426-33
11. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 2003;12:456-62
12. Heijl A, Leske M, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol 2002;120:1268-78
13. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
14. Gordon M, Beiser J, Brandt J, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20